

## NEW SCIENTIFIC ARTICLE HIGHLIGHTS GOOD HEALING RESULTS FOR CINCLUS PHARMA'S DRUG CANDIDATE LINAPRAZAN GLURATE FOR THE TREATMENT OF EGERD

**Cinclus Pharma AB (publ), a developer of drugs for the treatment of gastric acid-related diseases, announced today that a scientific article has been published with data from a phase II study showing high healing rates for patients with severe forms of erosive gastroesophageal reflux disease, eGERD. The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases.**

The article, titled *Randomised Controlled Trial: A Dose-Finding Study of Linaprazan glurate, A Novel Potassium Competitive Acid Blocker, vs. Lansoprazole for the Treatment of Erosive Esophagitis*, has been published online in the scientific journal *Alimentary Pharmacology & Therapeutics* and is written by Prateek Sharma, Michael Vaezi, Peter Unge, Kjell Andersson, Kajsa Larsson, Ivan Popadiyn, Maria Rosenholm, Andras Rosztóczy, Elham Yektaei and David Armstrong.

The published article presents data from a phase II clinical trial in which the treatment with linaprazan glurate (the next generation of PCAB) showed a high healing rate among patients suffering from eGERD.

For patients who were not healed after eight weeks of treatment with proton pump inhibitor, the best-performing dose of linaprazan glurate achieved a 100 percent healing rate after four weeks, a higher rate of 28 percentage points compared to the treatment with the proton pump inhibitor lansoprazole. The healing rate for patients with moderate to severe eGERD was 93 percent, which was 50 percentage points higher than the treatment with lansoprazole.

The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases.

"The study shows very good healing rates, both for patients previously treated with PPI without being healed and for patients with severe eGERD, which highlights the potential of our drug candidate. We look forward to initiating the phase III program of linaprazan glurate during 2025", says Kajsa Larsson, Chief Medical Officer at Cinclus Pharma.

"The results show how effective treatment with linaprazan glurate is compared to today's standard treatment, and in extension also the first generation of PCAB. Cinclus Pharma's drug meets the medical need of the patients who suffer the most with the severe forms of eGERD, which constitutes a large market with blockbuster potential," said Christer Ahlberg,

CEO of Cinclus Pharma.

To access the article, please click the following link: <http://doi.org/10.1111/apt.70109>

**For additional information, please contact:**

---

Christer Ahlberg, CEO  
Phone: +46 70 675 33 30  
e-mail: [christer.ahlberg@cincluspharma.com](mailto:christer.ahlberg@cincluspharma.com)

Henrik Vikström, IR  
Phone: +46 70 952 80 06  
e-mail: [henrik.vikstrom@cincluspharma.com](mailto:henrik.vikstrom@cincluspharma.com)

**About Cinclus Pharma**

---

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit [www.cincluspharma.com](http://www.cincluspharma.com).

**Attachments**

---

**New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD**